The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer
This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aro...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.759595/full |
| _version_ | 1818855413480685568 |
|---|---|
| author | Yi-Kun Kang Xue Wang Nan-Lin Hu Jian Yue Yi-Ran Si Jie Ju Song-Lin Gao Peng Yuan |
| author_facet | Yi-Kun Kang Xue Wang Nan-Lin Hu Jian Yue Yi-Ran Si Jie Ju Song-Lin Gao Peng Yuan |
| author_sort | Yi-Kun Kang |
| collection | DOAJ |
| description | This study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aromatase inhibitors plus ovarian function suppression (AI+OFS) on lipid profiles during the 60 months of endocrine therapy in hormone receptor-positive patients aged <40 with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, and the secondary endpoints were the changes in lipid profiles. A total of 230 young patients were included with the mean age of 35.7 years old. The patients in TAM group had significantly lower incidence of 5-year lipid events than those in TAM+OFS group (7.4% versus 21.3%; P=0.016) and AI+OFS group (7.4% versus 21.6%; P=0.009). The incidence of fatty liver was significantly higher in TAM+OFS group than TAM group (52.5%versus 30.9%; P=0.043). Lipid events were associated with younger age (odds ratio (OR)=0.865, 95% confidence interval (CI): 0.780-0960; P=0.006), higher baseline LDL-C (OR=14.959, 95% CI: 4.379-51.105; P<0.001), and use of OFS (OR=3.557, 95% CI: 1.151-10.989; P=0.027). Therefore, application of OFS, with younger age and higher baseline LDL-C, may increase the incidence of lipid events in premenopausal breast cancer. More care should be taken for lipid profiles during the endocrine therapy for young breast cancer patients. |
| first_indexed | 2024-12-19T08:08:13Z |
| format | Article |
| id | doaj.art-d565b46f58e94209ae692e62c04d97b9 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-19T08:08:13Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d565b46f58e94209ae692e62c04d97b92022-12-21T20:29:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-12-011110.3389/fonc.2021.759595759595The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast CancerYi-Kun KangXue WangNan-Lin HuJian YueYi-Ran SiJie JuSong-Lin GaoPeng YuanThis study aimed to evaluate and compare the effects of various endocrine therapies on lipid profiles in young patients with breast cancer. A retrospective, single-center study was performed to investigate the effects of tamoxifen (TAM), tamoxifen plus ovarian function suppression (TAM+OFS), and aromatase inhibitors plus ovarian function suppression (AI+OFS) on lipid profiles during the 60 months of endocrine therapy in hormone receptor-positive patients aged <40 with early breast cancer. The primary endpoint was the cumulative incidence of lipid events, and the secondary endpoints were the changes in lipid profiles. A total of 230 young patients were included with the mean age of 35.7 years old. The patients in TAM group had significantly lower incidence of 5-year lipid events than those in TAM+OFS group (7.4% versus 21.3%; P=0.016) and AI+OFS group (7.4% versus 21.6%; P=0.009). The incidence of fatty liver was significantly higher in TAM+OFS group than TAM group (52.5%versus 30.9%; P=0.043). Lipid events were associated with younger age (odds ratio (OR)=0.865, 95% confidence interval (CI): 0.780-0960; P=0.006), higher baseline LDL-C (OR=14.959, 95% CI: 4.379-51.105; P<0.001), and use of OFS (OR=3.557, 95% CI: 1.151-10.989; P=0.027). Therefore, application of OFS, with younger age and higher baseline LDL-C, may increase the incidence of lipid events in premenopausal breast cancer. More care should be taken for lipid profiles during the endocrine therapy for young breast cancer patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.759595/fullendocrine therapylipidbreast cancerpremenopausalovarian function suppression |
| spellingShingle | Yi-Kun Kang Xue Wang Nan-Lin Hu Jian Yue Yi-Ran Si Jie Ju Song-Lin Gao Peng Yuan The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer Frontiers in Oncology endocrine therapy lipid breast cancer premenopausal ovarian function suppression |
| title | The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer |
| title_full | The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer |
| title_fullStr | The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer |
| title_full_unstemmed | The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer |
| title_short | The Effects of Endocrine Therapies on Lipid Profiles in Chinese Young Women With Early Breast Cancer |
| title_sort | effects of endocrine therapies on lipid profiles in chinese young women with early breast cancer |
| topic | endocrine therapy lipid breast cancer premenopausal ovarian function suppression |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.759595/full |
| work_keys_str_mv | AT yikunkang theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT xuewang theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT nanlinhu theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT jianyue theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT yiransi theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT jieju theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT songlingao theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT pengyuan theeffectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT yikunkang effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT xuewang effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT nanlinhu effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT jianyue effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT yiransi effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT jieju effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT songlingao effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer AT pengyuan effectsofendocrinetherapiesonlipidprofilesinchineseyoungwomenwithearlybreastcancer |